...from cell therapy companies Atara Biotherapeutics Inc. (NASDAQ:ATRA) and Poseida Therapeutics Inc....

...engineered cell therapy plays have non-viral transposon platforms: Poseida Therapeutics Inc....

...company to go public (see “Interest in Protein Degradation Runs Hot”).Poseida tumbles after clinical holdNewly public Poseida Therapeutics Inc....
...sodium-dependent bile acid transporter member 2 BC Staff P-PSMA-101 Goofice (Brand), AJG533 (Compound #), A3309 (Compound #), elobixibat (Generic) Poseida Therapeutics Inc. Albireo...

...Kingsley will become president and CEO after CEO Nagesh Mahanthappa steps down on Aug. 1. Poseida Therapeutics Inc....
...Sawka, BioCentury Staff ViaCyte Inc. Ribon Therapeutics Inc. Innate Pharma S.A. Kiadis Pharma N.V. Zikani Therapeutics Inc. Tarsus Pharmaceuticals Inc. MaaT Pharma S.A. Neurogene Poseida Therapeutics Inc. Poseida Therapeutics AnaptysBio...

...among three that began trading on NASDAQ Friday. Also pricing offerings were CAR T company Poseida Therapeutics Inc....
...gains in the aftermarket (see “Data Bytes: Queue Remains Hot” ). Paul Bonanos, Associate Editor Nkarta Inc. Inventiva S.A. Poseida Therapeutics Inc....

...first time Friday, one of which is also seeking an offering upwards of $200 million. Poseida Therapeutics Inc....
...enjoyed big gains in the aftermarket (see “Data Bytes: Queue Remains Hot” ). Paul Bonanos, Associate Editor Poseida Therapeutics Inc. Nkarta...

...indications this year and next (see “AlloVir First to Test ElevateBio’s Model” ). Meanwhile, both Poseida Therapeutics Inc....

...to line up for public market debuts (see “Biotech IPOs on NASDAQ Maintain Momentum” ). Poseida Therapeutics Inc....
...member 17 TIGIT - T cell immunoreceptor with Ig and ITIM domains Elizabeth S. Eaton, Staff Writer Poseida Therapeutics Inc. iTeos...

...more biotechs entered the NASDAQ queue late Friday. Among them is CAR T therapeutics developer Poseida Therapeutics Inc....

...develop allogeneic CAR T cell therapies. The partnerships was transferred to Transposagen’s human therapeutics spinout Poseida Therapeutics Inc....